Genmab A/S’s (GMAB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research report released on Monday morning, MarketBeat.com reports. They currently have a $40.00 price target on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q3 2026 earnings at $0.49 EPS, Q4 2026 earnings at $0.44 EPS, FY2026 earnings at $1.48 EPS and FY2027 earnings at $1.48 EPS.

GMAB has been the topic of a number of other research reports. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. New Street Research set a $43.00 price objective on Genmab A/S in a research note on Wednesday, July 22nd. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and upped their price target for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. Guggenheim raised their price objective on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Truist Financial initiated coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Genmab A/S Trading Up 0.7%

GMAB stock opened at $34.40 on Monday. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The company has a market cap of $21.46 billion, a price-to-earnings ratio of 27.09, a PEG ratio of 1.86 and a beta of 0.84. The business has a fifty day simple moving average of $31.29 and a 200-day simple moving average of $28.35. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. On average, equities research analysts expect that Genmab A/S will post 1.21 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after purchasing an additional 1,334,919 shares during the period. First Trust Advisors LP lifted its position in Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares during the period. UBS Group AG boosted its stake in shares of Genmab A/S by 124.2% during the 4th quarter. UBS Group AG now owns 184,191 shares of the company’s stock valued at $5,673,000 after buying an additional 102,021 shares during the period. Finally, Cibc World Market Inc. grew its holdings in shares of Genmab A/S by 31.2% during the 4th quarter. Cibc World Market Inc. now owns 367,282 shares of the company’s stock valued at $11,312,000 after acquiring an additional 87,350 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.